Flow Traders U.S.’s Alexion Pharmaceuticals ALXN Stock Holding History

Flow Traders U.S.’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-3,000	Closed	-$367K	–	563
2016 Q4	$367K	Buy	+3,000	New	+$367K	0.02%	240

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Flow Traders U.S.'s ALXN Position: Q1 2017 in Review

Flow Traders U.S. sold out of Alexion Pharmaceuticals (ALXN) in Q1 2017, closing a stake of 3,000 shares — an estimated $367K sold.

Flow Traders U.S. first reported a position in ALXN in Q4 2016 and held it in 1 quarter. The position peaked at $367K in Q4 2016. 561 funds tracked by Wall St. Rank hold ALXN as of Q1 2017.

Flow Traders U.S. reported no remaining Alexion Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Flow Traders U.S. sold 3,000 Alexion Pharmaceuticals shares in Q1 2017, an estimated $367K.
Flow Traders U.S. first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 1 quarter.
Flow Traders U.S.'s Alexion Pharmaceuticals position peaked at $367K in Q4 2016.
561 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2017.

Based on Flow Traders U.S.'s 13F filing for Q1 2017, filed 15 May 2017.